Sjögren's disease · checked 2026-09-25

Four treatment trials enrolling in the US right now.

A raw ClinicalTrials.gov search for Sjögren's returns eight recruiting studies with US sites. Four test a treatment for Sjögren's itself. This is the four, in plain language, and the other four with a line on what they actually are.

• CLN-978

  Early (Phase 1)

  A CD19-directed T-cell engager given under the skin. An "off-the-shelf" immune-reset approach: it directs your own T cells to remove the B cells that drive the disease, without harvesting cells or chemotherapy.

  Cullinan Therapeutics · 36 people · NCT07041099 on ClinicalTrials.gov

• AlloNK with rituximab

  In trials (Phase 2)

  Donor-derived natural killer cells combined with rituximab, to remove B cells more completely, in relapsing B-cell-driven rheumatic diseases including Sjögren's.

  Artiva Biotherapeutics · 90 people · NCT06991114 on ClinicalTrials.gov

• Tofacitinib

  In trials (Phase 2)

  An oral JAK inhibitor already approved for rheumatoid arthritis, studied for safety in primary Sjögren's.

  NIDCR, National Institutes of Health · 60 people · NCT07281456 on ClinicalTrials.gov

• Acoltremon eye drops (Tryptyr)

  Approved drug, new setting (Phase 4)symptom treatment

  An approved dry-eye drop evaluated specifically for Sjögren's dry eye. A symptom treatment, not a treatment for the disease itself.

  Center For Sight · 35 people · NCT07277257 on ClinicalTrials.gov

Stage language: Approved means available now. In trials means promising, not yet. Early means one to watch. Sites and eligibility are on ClinicalTrials.gov under each ID; eligibility is set by the trial, not by us.

Also listed by the registry

The same search returns these. None is a treatment trial for Sjögren's.

• Sanford CoRDS rare disease registry (NCT01793168): A registry, not a treatment. It accepts people with Sjögren's who want to contribute to research without taking a drug.
• Unhide Project (NCT04806620): A lifestyle-data platform for brain inflammation research.
• Myelin Disorders Biorepository (NCT03047369): A pediatric biorepository.
• AIM-NIVO (NCT03816345): A cancer immunotherapy study in people who also have an autoimmune disease.

And ianalumab

Ianalumab's two Phase 3 trials (NEPTUNUS-1 and NEPTUNUS-2) finished enrolling, which is why they are not above. It received FDA Breakthrough Therapy designation on 16 January 2026, and a decision is expected in the coming months. A further Phase 3 for people with high symptom burden is registered (NCT07621809); we will add it the day it opens.

Get the FDA decision the hour it lands →

For information only. Not medical advice. We are not doctors. Bring what you learn to your care team.